Physician profile
Pranathi Lingam
NPI 1821324963
$4,238.47
in general payments reported to CMS, 2019-2025
25 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2021: $387 · 2022: $713 · 2023: $536 · 2024: $1,254 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.00 |
| Education | $180.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $513.89 | 2021-2025 | Dupixent |
| Pfizer INC. | $450.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $447.09 | 2021-2025 | |
| Janssen Biotech, INC. | $425.71 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $412.33 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $291.78 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $191.63 | 2023-2025 | |
| Leo Pharma INC. | $175.14 | 2023-2025 | Adbry, Anzupgo |
| Janssen Scientific Affairs, LLC | $118.32 | 2022 | |
| Sun Pharmaceutical Industries INC. | $65.91 | 2021-2024 | |
| Incyte Corporation | $64.04 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $58.79 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $53.40 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.78 | 2023-2025 | Jublia, Cabtreo, Siliq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $30.14 | 2024 | Filsuvez |
| Galderma Laboratories, L.P. | $29.17 | 2025 | Nemluvio |
| Amgen INC. | $27.28 | 2019-2024 | Otezla |
| Blueprint Medicines Corporation | $23.44 | 2025 | Ayvakit |
| Amryt Pharma Holdings LTD | $19.55 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.33 | 2023 | Ycanth |
| Glaxosmithkline, LLC. | $14.65 | 2019 | |
| Biogen, INC. | $14.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2024 | Spevigo |
| Organon LLC | $3.11 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranathi Lingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.